Home > Oncology > ASCO 2020 > HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

In an initial report of patients with heavily pre-treated metastatic, HER2-expressing colorectal cancer (mCRC), preliminary efficacy was observed with trastuzumab deruxtecan, particularly in patients with the highest degree of HER2 positivity.

Prof. Salvatore Siena (University of Milan Niguarda Cancer Center, Italy) presented results from the DESTINY-CRC01 study, which stratified 3 cohorts of patients [1]. Cohort A had HER2-overexpressing patients who had scores of 3 or higher according to immunohistochemistry testing (IHC 3 plus), as well as a score above 2 by *in situ* hybridisation (ISH). Cohort B were patients whose tumours were IHC 2 and above but were ISH-negative; cohort C were patients whose tumours were IHC >1. All patients (n=90) enrolled in the trial had tumours that were *RAS/BRAF* wildtype and expressed HER2. A single patient had an *NRAS* mutation. All had received at least 2 prior...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on